Abbott Laboratories (ABT) revenue breakdown
By segment, Medical Devices is the largest at 48% of fiscal 2025 revenue, growing 10% a year over 8 years.
By region, United States is the largest at 39% of fiscal 2025 revenue; Germany grew fastest, 11% a year over 9 years.
Revenue by segment
Fiscal years, as Abbott Laboratories reports them in its 10-K filings; fiscal 2025 total $44.3B.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $10.3B | $11.4B | $12.2B | $11.8B | $14.5B | $14.8B | $16.9B | $19.0B | $21.4B | 48% |
| Diagnostics | $5.6B | $7.5B | $7.7B | $10.8B | $15.5B | $16.5B | $10.0B | $9.3B | $8.9B | 20% |
| Nutritionals | $6.9B | $7.2B | $7.4B | $7.6B | $8.3B | $7.5B | $8.2B | $8.4B | $8.5B | 19% |
| Established Pharmaceuticals | $4.3B | $4.4B | $4.5B | $4.3B | $4.7B | $4.9B | $5.1B | $5.2B | $5.5B | 12% |
| Other | $237M | $62M | $57M | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Abbott Laboratories reports them in its 10-K filings; fiscal 2025 total $44.3B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $6.5B | $9.7B | $10.8B | $11.4B | $13.0B | $16.6B | $18.1B | $15.5B | $16.3B | $17.1B | 39% |
| All Other Countries | $8.0B | $9.9B | $11.2B | $11.9B | $12.8B | $15.7B | $15.0B | $14.2B | $14.8B | $16.0B | 36% |
| Germany | $1.0B | $1.4B | $1.6B | $1.8B | $2.1B | $2.6B | $2.3B | $2.3B | $2.5B | $2.8B | 6% |
| China | $1.7B | $2.1B | $2.3B | $2.3B | $2.0B | $2.4B | $2.1B | $2.3B | $2.1B | $1.9B | 4% |
| Switzerland | $766M | $841M | $1.0B | $1.1B | $1.1B | $1.3B | $1.3B | $1.6B | $1.7B | $1.9B | 4% |
| India | $1.1B | $1.2B | $1.3B | $1.4B | $1.3B | $1.6B | $1.6B | $1.8B | $1.8B | $1.9B | 4% |
| Japan | $924M | $1.3B | $1.3B | $1.4B | $1.4B | $1.7B | $1.9B | $1.5B | $1.4B | $1.5B | 3% |
| United Kingdom | — | — | — | — | — | — | — | $991M | $1.2B | $1.3B | 3% |
| Netherlands | — | — | — | — | — | $1.2B | $1.1B | — | — | — | — |
| The Netherlands | $830M | $929M | $930M | — | — | — | — | — | — | — | — |
| Canada | — | — | — | $573M | $841M | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABT.
Open ABT in InvestinglyQuestions
Where does Abbott Laboratories make its money?
In fiscal 2025, by segment: Medical Devices $21.4B, Diagnostics $8.9B, Nutritionals $8.5B, Established Pharmaceuticals $5.5B.
From Abbott Laboratories's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.